Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efprezimod alfa for Acute GVHD Prevention
NCT02663622Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2016
- Primary completion
- Jun 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efprezimod alfa in Acute Graft-Versus-Host Disease (aGvHD) (4 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event at 62 days, Number of Participants Who Discontinued Study Treatment Due to an AE at 30 days and 2 more. Started Sep 2016; status: completed.
02
Drugs
efprezimod alfa
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02663622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02663622.